Phase III success for Moderna (Nasdaq: MRNA) will help the company catch up with rivals GSK (LSE: GSK) and Pfizer (NYSE: PFE) in the upcoming battle to treat respiratory syncytial virus (RSV) infections.
Moderna's shares rose 6.7% to $203.55 on the news.
Moderna’s competitors have already filed for US approval for their respective options, under the US Food and Drug Administration’s priority review scheme, and could launch in the second quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze